FIGURE 2. Activity Profiles of Rapid-, Intermediate-, and Long-Acting Insulins

Data compiled from Council for the Advancement of Diabetes Research and Education (CADRE). Core slide kit. Section 6: therapeutic options: insulins. 2011. www.cadre-diabetes.org/r_slide_show.asp?id=7. Accessed August 2, 2012; Hirsch IB. Optimal initiation of insulin in type 2 diabetes. Medscape Gen Med. 2005;7:49. www.medscape.com/viewarticle/515847; Danne T, Lupke K, Walte K, et al. Insulin detemir is characterized by a consistent pharmacokinetic profile across age-groups in children, adolescents, and adults with type 1 diabetes. Diabetes Care. 2003;26:3087-3092; Porcellati F, Rossetti P, Busciantella NR, et al. Comparison of pharmacokinetics and dynamics of the long-acting insulin analogs glargine and detemir at steady state in type 1 diabetes: a double-blind, randomized, crossover study. Diabetes Care. 2007;30(10):2447-2452.